TRIAFEMI CONTINU, tablet 84 tablets
Active ingredients: Norgestimate, Ethinylestradiol
Commercialized according to BDPMDispensing in France: Prescription only
Tablet84 tabletsorale
No current ANSM shortage notice is included
Package details
Original BDPM fields are shown in French.
- Official name
- TRIAFEMI CONTINU, comprimé
- Pharmaceutical form
- comprimé(s)
- Route of administration
- orale
- Presentation description
- 3 plaquette(s) thermoformée(s) PVC PVDC aluminium de 28 comprimés (7 comprimés blancs, 7 comprimés bleu ciel, 7 comprimés bleu foncé et 7 comprimés roses)
- Marketing authorisation holder
- EFFIK
- Reimbursement according to BDPM
- —
- Approval for use in healthcare institutions
- non
- Commercialization declaration date
- 29 Aug 2025
- Prescription and dispensing conditions
- Prescription only
- List I: prescription-only medicine
- Enhanced ANSM monitoring
- No
BDPM identifiers
CIS
69090320CIP73029404CIP133400930294048Composition in BDPM
| Component | Amount per unit | Source type |
|---|---|---|
| ÉTHINYLESTRADIOLcomprimé blanc | 0,035 mg · un comprimé | SA |
| NORGESTIMATEcomprimé blanc | 0,18 mg · un comprimé | SA |
| ÉTHINYLESTRADIOLcomprimé bleu ciel | 0,035 mg · un comprimé | SA |
| NORGESTIMATEcomprimé bleu ciel | 0,215 mg · un comprimé | SA |
| ÉTHINYLESTRADIOLcomprimé bleu foncé | 0,035 mg · un comprimé | SA |
| NORGESTIMATEcomprimé bleu foncé | 0,25 mg · un comprimé | SA |
Information is based on BDPM data and is for reference only. Consult a doctor before use.
Similar medicines
Similar medicines are listed using the official BDPM catalog. Availability must be checked separately. Consult a doctor or pharmacist before switching medicines.
The current BDPM data does not list similar medicines for this product.